122
Participants
Start Date
April 30, 2010
Primary Completion Date
May 31, 2012
Study Completion Date
May 31, 2012
IPI-926 plus gemcitabine
Daily IPI-926 (oral) at 160 mg plus gemcitabine (infusion) at 1000 mg/m2 once weekly for 3 weeks of a 28 day cycle
Placebo plus gemcitabine
Daily Oral placebo/IPI-926 160 mg plus gemcitabine infusion at 1000 mg/m2 once every 3 weeks in a 28 day cycle
Columbia University Medical Center, New York
Weill Cornell Medical Center, New York
University of Rochester, Rochester
Virginia Oncology Associates, Newport News
Institute of Translational Oncology Research, Greenville
H. Lee Moffitt Cancer Center and Research Institute, Tampa
Norton Health Care, Louisville
West Michigan Cancer Center, Kalamazoo
Kansas City Cancer Center, Overland Park
Texas Oncology, PA, Dallas
Tyler Cancer Center, Tyler
University of Colorado Cancer Center, Aurora
Arizona Clinical Research Center, Tucson
Kaiser Permanente, Vallejo
Providence Portland Medical Center, Portland
Willamette Valley Cancer Institute and Research Center, Eugene
Seattle Cancer Care Alliance, Seattle
University of California San Diego Medical Center, San Diego
University of California San Francisco, San Francisco
Hackensack University Medical Center, Hackensack
University of Pittsburgh Medical Center, Pittsburgh
Rhode Island Hospital, Providence
Texas Oncology- Bedford, Bedford
South Texas Oncology and Hematology, San Antonio
Jewish General Hospital, Montreal
Dana-Farber Cancer Institute, Boston
Cancer Care Manitoba, Winnipeg
Toronto Sunnybrook Regional Cancer Centre, Toronto
Lead Sponsor
Infinity Pharmaceuticals, Inc.
INDUSTRY